The SAATELLITE and EVADE Clinical Studies Within the COMBACTE Consortium: A Public-Private Collaborative Effort in Designing and Performing Clinical Trials for Novel Antibacterial Drugs to Prevent Nosocomial Pneumonia.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 27481953.
- Also identified by DOI 10.1093/cid/ciw245.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The Innovative Medicines Initiative-funded COMBACTE consortium fosters academic-industry partnership in pioneering studies to combat serious bacterial infections. We describe how this partnership is advancing the development of 2 monoclonal antibodies, MEDI4893 and MEDI3902, for the prevention of nosocomial pneumonia.
Medical subject headings
- Anti-Bacterial Agents
- Antibodies, Monoclonal
- Cross Infection
- Drug Discovery
- Pneumonia, Bacterial
- Public-Private Sector Partnerships